Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353383 | 0.88 | CYP1A2 (0.49) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL28784166 | 0.88 | CA1 (0.45) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL27761910 | 0.88 | CA1 (0.45) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL27490793 | 0.87 | MEN1 (0.45) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL7804302 | 0.83 | TDP1 (0.50) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL628885 | 0.83 | CTSK (0.57) | CTSKCTSS | |
| SCHEMBL5031624 | 0.82 | CA1 (0.45) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL15015920 | 0.82 | MEN1 (0.44) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL1837431 | 0.81 | CA2 (0.47) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL2239345 | 0.81 | CTSK (0.52) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |